<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002044</url>
  </required_header>
  <id_info>
    <org_study_id>014D</org_study_id>
    <secondary_id>14</secondary_id>
    <nct_id>NCT00002044</nct_id>
  </id_info>
  <brief_title>A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases</brief_title>
  <official_title>A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to evaluate the efficacy of Retrovir (AZT) in the&#xD;
      treatment of AIDS-related dementia and various neuromuscular complications. HIV is both a&#xD;
      lymphotropic and neurotropic virus which can affect both the central and peripheral nervous&#xD;
      systems (CNS, PNS). There is evidence that the CNS and PNS may harbor the virus in a latent&#xD;
      state, with the potential for continuous reinfection of other body systems. Therefore,&#xD;
      effective therapeutic efforts against HIV infection should provide effective antiviral&#xD;
      activity within the nervous system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>AIDS Dementia Complex</condition>
  <condition>Neuromuscular Diseases</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Past or present renal disease.&#xD;
&#xD;
          -  Significant bone marrow suppression.&#xD;
&#xD;
          -  Blood transfusion within the past month.&#xD;
&#xD;
          -  Liver dysfunction.&#xD;
&#xD;
          -  Evidence of an underlying, severe infection.&#xD;
&#xD;
          -  Evidence of an active life-threatening opportunistic infection at study entry.&#xD;
&#xD;
          -  Severe malabsorption (patients with recent significant weight loss must have a serum&#xD;
             carotene level of &gt; 75 IU/ml).&#xD;
&#xD;
          -  Evidence of nervous system dysfunction being caused by factors other than HIV&#xD;
             infection, particularly by cerebral toxoplasmosis, lymphoma, cryptococcal meningitis,&#xD;
             chronic alcohol abuse, lead poisoning, cytomegalovirus (CMV) infection (patients with&#xD;
             retinal CMV infection or other evidence of CMV dementia), syphilis, or progressive&#xD;
             multifocal leukoencephalopathy.&#xD;
&#xD;
          -  Other known causes of nerve or muscle disease.&#xD;
&#xD;
          -  Hypersensitivity to zidovudine (AZT).&#xD;
&#xD;
          -  Lymphoma or other tumor requiring cytotoxic chemotherapy.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Electron beam therapy to an area of less than 100 cm2.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Past or present renal disease.&#xD;
&#xD;
          -  Significant bone marrow suppression.&#xD;
&#xD;
          -  Blood transfusion within the past month.&#xD;
&#xD;
          -  Liver dysfunction.&#xD;
&#xD;
          -  Evidence of an underlying, severe infection.&#xD;
&#xD;
          -  Evidence of an active life-threatening opportunistic infection at study entry.&#xD;
&#xD;
          -  Severe malabsorption (patients with recent significant weight loss must have a serum&#xD;
             carotene level of &gt; 75 IU/ml).&#xD;
&#xD;
          -  Evidence of nervous system dysfunction being caused by factors other than HIV&#xD;
             infection, particularly by cerebral toxoplasmosis, lymphoma, cryptococcal meningitis,&#xD;
             chronic alcohol abuse, lead poisoning, cytomegalovirus (CMV) infection (patients with&#xD;
             retinal CMV infection or other evidence of CMV dementia), syphilis, or progressive&#xD;
             multifocal leukoencephalopathy.&#xD;
&#xD;
          -  Other known causes of nerve or muscle disease.&#xD;
&#xD;
          -  Hypersensitivity to zidovudine (AZT).&#xD;
&#xD;
          -  Lymphoma or other tumor requiring cytotoxic chemotherapy.&#xD;
&#xD;
        Patients with AIDS (CDC surveillance definition) or AIDS related complex (ARC).&#xD;
&#xD;
          -  All patients must have either:&#xD;
&#xD;
          -  Dementia as defined by a progressive cognitive impairment in the absence of altered&#xD;
             consciousness that is thought to be causally related to HIV infection. Patients in&#xD;
             this study will fall into the lower 20 percent (or less) of a normal sample of formal&#xD;
             neuropsychological testing.&#xD;
&#xD;
          -  OR&#xD;
&#xD;
          -  One of the following neuromuscular diseases thought to be related to HIV infection:&#xD;
&#xD;
          -  Demyelinating polyneuropathy, axonal polyneuropathy, inflammatory myopathy, or&#xD;
             unexplained progressive muscle weakness.&#xD;
&#xD;
          -  Capacity to give informed consent or a person with durable power of attorney who can&#xD;
             give informed consent.&#xD;
&#xD;
          -  Life expectancy = or &gt; 4 months.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Immunomodulating agents.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy (except electron beam therapy to an area of less than 100 cm2).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
          -  Any retroviral drug including but not limited to zidovudine (AZT), ribavirin, HPA 23,&#xD;
             AL721, or phosphonoformate.&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Immunomodulating agents.&#xD;
&#xD;
          -  An anticipated need for any of these agents within the next 16 weeks.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 1 month of study entry:&#xD;
&#xD;
          -  Radiation therapy (except electron beam therapy to an area of less than 100 cm2).&#xD;
&#xD;
          -  Blood transfusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glaxo Wellcome Inc</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <zip>27709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Pilot Projects</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS Dementia Complex</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>AIDS Dementia Complex</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

